JP6906047B2 - 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 - Google Patents

特異的炎症収束性メディエーターの塩に関連する組成物及び方法 Download PDF

Info

Publication number
JP6906047B2
JP6906047B2 JP2019515785A JP2019515785A JP6906047B2 JP 6906047 B2 JP6906047 B2 JP 6906047B2 JP 2019515785 A JP2019515785 A JP 2019515785A JP 2019515785 A JP2019515785 A JP 2019515785A JP 6906047 B2 JP6906047 B2 JP 6906047B2
Authority
JP
Japan
Prior art keywords
compound
rve1
disease
lxa4
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517582A5 (https=
JP2019517582A (ja
Inventor
シャヴォリーノ，フランク・シー
マティアス，ゲーリー
バン・ザント，マイケル・シー
ジャグドマン，ガンナー・エリック，ジュニア
ドォラク，ジェシカ・ジェイ
Original Assignee
テティス・ファーマシューティカルズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テティス・ファーマシューティカルズ・エルエルシー filed Critical テティス・ファーマシューティカルズ・エルエルシー
Publication of JP2019517582A publication Critical patent/JP2019517582A/ja
Publication of JP2019517582A5 publication Critical patent/JP2019517582A5/ja
Priority to JP2021106306A priority Critical patent/JP7130818B2/ja
Application granted granted Critical
Publication of JP6906047B2 publication Critical patent/JP6906047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019515785A 2016-06-03 2017-06-02 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 Active JP6906047B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021106306A JP7130818B2 (ja) 2016-06-03 2021-06-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345043P 2016-06-03 2016-06-03
US62/345,043 2016-06-03
PCT/US2017/035752 WO2017210604A1 (en) 2016-06-03 2017-06-02 Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021106306A Division JP7130818B2 (ja) 2016-06-03 2021-06-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019517582A JP2019517582A (ja) 2019-06-24
JP2019517582A5 JP2019517582A5 (https=) 2020-07-16
JP6906047B2 true JP6906047B2 (ja) 2021-07-21

Family

ID=59325604

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019515785A Active JP6906047B2 (ja) 2016-06-03 2017-06-02 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2020529300A Active JP7368354B2 (ja) 2016-06-03 2018-11-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2021106306A Active JP7130818B2 (ja) 2016-06-03 2021-06-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020529300A Active JP7368354B2 (ja) 2016-06-03 2018-11-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2021106306A Active JP7130818B2 (ja) 2016-06-03 2021-06-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法

Country Status (10)

Country Link
US (5) US10130719B2 (https=)
EP (3) EP3454907B1 (https=)
JP (3) JP6906047B2 (https=)
KR (1) KR102437682B1 (https=)
CN (2) CN109562186B (https=)
AU (1) AU2018374863B2 (https=)
CA (2) CA3026264A1 (https=)
DK (1) DK3454907T3 (https=)
ES (1) ES2827796T3 (https=)
WO (2) WO2017210604A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
US20220040136A1 (en) 2018-10-09 2022-02-10 University Of Rochester Treatment of vulvovaginal disorders
US11400057B2 (en) 2018-10-19 2022-08-02 University Of Rochester Treatment of vulvar pain
GB201913383D0 (en) * 2019-09-17 2019-10-30 Univ London Queen Mary Methods for predicting patient response to DMARDs
EP4157252A4 (en) * 2020-06-01 2024-08-14 Balchem Corporation DIAMINOACID METAL CHELATES OR TRIAMINOACID METAL CHELATES
US11986512B2 (en) * 2021-10-26 2024-05-21 Thetis Phamaceuticals LLC Compositions and methods for cancer therapy
IL315234A (en) 2022-03-03 2024-10-01 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599152A (en) 1985-05-24 1986-07-08 Albion Laboratories Pure amino acid chelates
US4863898A (en) 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5061815A (en) 1988-07-06 1991-10-29 Zinpro Corporation Metal lysine complexes and method for producing metal lysine complexes
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
DE69115990T2 (de) 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
IT1264987B1 (it) 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US6517870B1 (en) 1998-04-29 2003-02-11 Sumitomo Pharmaceuticals Company, Limited Oral formulation comprising biguanide and an organic acid
JP4526622B2 (ja) 1998-10-23 2010-08-18 北興化学工業株式会社 農園芸用種子消毒剤および種子の消毒方法
JP2000212145A (ja) 1999-01-22 2000-08-02 Hokko Chem Ind Co Ltd Ｎε―アシル―４―オキサリジンおよびその製造用中間体
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US7105572B2 (en) 2000-02-04 2006-09-12 Takeda Pharmaceutical Company Limited Stable emulsion compositions
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
DE10102050A1 (de) 2001-01-17 2002-07-18 Basf Ag Zubereitung zur Verbesserung der Nahrungsverwertung
PT1406698E (pt) 2001-03-02 2009-01-12 Brigham & Womens Hospital Análogos de lipoxina como novos inibidores da angiogénese
CA2442106A1 (en) 2001-03-29 2002-10-10 Basf Aktiengesellschaft Conjugated unsaturated glyceride mixtures and a method for producing the same
EP1429602B1 (en) 2001-08-31 2009-12-16 Rutgers, The State University Of New Jersey Methods for treating disorders using plant extracts
JP4652685B2 (ja) 2001-11-06 2011-03-16 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
AU2003211131A1 (en) 2002-02-14 2003-09-04 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
WO2003093449A2 (en) 2002-05-06 2003-11-13 Nucleonics, Inc. Methods for delivery of nucleic acids
JP2005529945A (ja) 2002-06-17 2005-10-06 リソルヴィックス ファーマシューティカルズ オメガ−３ｐｕｆａ由来の脂質メディエーターの類似体及び使用方法
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
AU2003261298A1 (en) 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
EP2384750A1 (en) 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
US7547454B2 (en) 2002-11-07 2009-06-16 Shyam K Gupta Hydroxy acid complexes for antiaging and skin renovation
JP2004175790A (ja) 2002-11-12 2004-06-24 Arita Junichi α−グルコシダーゼ阻害作用を有する亜鉛含有物
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
JP2006520335A (ja) 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
EP1624858B1 (en) 2003-04-09 2018-06-06 Rutgers, the State University of New Jersey Novel encochleation methods
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20080045559A1 (en) 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
BRPI0415858A (pt) 2003-10-29 2007-01-09 Sonus Pharma Inc compostos de medicamentos terapêuticos modificados por tocoferol
EP1677759A1 (en) 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
AU2005205882A1 (en) 2004-01-22 2005-08-04 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
EP1591114A1 (en) 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20060003976A1 (en) 2004-06-04 2006-01-05 Yuehua Zhang Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
TWI236573B (en) 2004-07-09 2005-07-21 Asia Optical Co Inc Camera lens with adjustment mechanism
CN101094683A (zh) 2004-10-29 2007-12-26 J·坎贝尔－托夫特 从催吐萝芙木和酸橙中分离的抗糖尿病提取物及其使用方法
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
CA2613875C (en) 2005-07-04 2018-09-25 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US20100121048A1 (en) 2006-02-16 2010-05-13 Takanobu Kuroita Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
US20090047340A1 (en) 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
CN101522658A (zh) 2006-06-16 2009-09-02 因迪基恩药物公司 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐
US20120189569A1 (en) 2006-08-06 2012-07-26 Bioderm Research Hydroxy Acid Complexes for Skin Renovation and Clarity
TW200816991A (en) * 2006-08-23 2008-04-16 Bayer Schering Pharma Ag Treatment and prevention of intestinal fibrosis
KR101438177B1 (ko) 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
US20100105773A1 (en) 2006-11-09 2010-04-29 The Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
PE20120395A1 (es) * 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
CN105152983A (zh) 2007-01-29 2015-12-16 韩诺生物制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
TW200904433A (en) 2007-04-27 2009-02-01 Takeda Pharmaceutical Substituted imidazole compound and use thereof
US20090054513A1 (en) 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
CN101855204B (zh) 2007-09-21 2013-09-11 韩兀生物制药株式会社 N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物
JP5441705B2 (ja) 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
CN105903005A (zh) 2008-05-05 2016-08-31 奥拉姆德有限公司 用于口服给予艾塞那肽的方法和组合物
CN102123990B (zh) 2008-06-19 2014-07-09 武田药品工业株式会社 杂环化合物及其用途
CN102159539B (zh) 2008-06-26 2014-04-16 矽烷实验室股份公司 用于血糖控制的新型二甲双胍甘氨酸盐
FR2934519B1 (fr) 2008-08-01 2013-06-28 Oreal Procede de fabrication d'un premier recipient de produit cosmetique, moule, col et recipient associes
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
WO2011034887A2 (en) 2009-09-15 2011-03-24 The Brigham And Women's Hospital, Inc. A method for treating neuropathic pain
PL217815B1 (pl) 2009-12-14 2014-08-29 Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością Napój izotoniczny z chelatami
US8178707B2 (en) 2010-03-25 2012-05-15 Jost Chemical Company Co-precipitated salts of fatty acids
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
EP2705844B1 (en) 2011-04-13 2019-05-22 Ajinomoto Co., Inc. Nutritional composition
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
JP2015511012A (ja) 2012-03-06 2015-04-13 ライフ テクノロジーズ コーポレーション 全身性エリテマトーデスのためのバイオマーカー
DK2858496T3 (da) 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140011814A1 (en) 2012-07-06 2014-01-09 Thetis Pharmaceuticals Llc Diamine and meglumine salt forms of fatty acids
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
EP2872483A4 (en) 2012-07-10 2016-03-16 Thetis Pharmaceuticals Llc THREE METFORMIN SALT FORM
WO2014011895A2 (en) 2012-07-11 2014-01-16 Thetis Pharmaceuticals Llc High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
AU2012227298B2 (en) 2012-09-25 2015-02-12 Jost Chemical Co. Co-precipitated salts of fatty acids
TW201416726A (zh) 2012-10-26 2014-05-01 Dongguan Masstop Liquid Crystal Display Co Ltd 具有觸控功能之彩色濾光片基板
US9394318B2 (en) 2012-11-30 2016-07-19 Cypress Pharmaceuticals, Inc. Crystal polymorph of magnesium glycinate dihydrate and process for its preparation
CN103340300A (zh) 2013-06-06 2013-10-09 李才平 一种绿色生态鲫鱼饲料的配制方法
WO2015171516A1 (en) * 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
CA2951923A1 (en) * 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9242008B2 (en) * 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN104430341B (zh) 2014-12-10 2016-09-28 青岛大学 天然有机酸根褐藻氨酸螯合物在农用制剂中的应用
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
GB201522132D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Vaccine
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación

Also Published As

Publication number Publication date
JP2021165281A (ja) 2021-10-14
CA3026264A1 (en) 2017-12-07
US11925688B2 (en) 2024-03-12
CN111902394A (zh) 2020-11-06
EP3795179A1 (en) 2021-03-24
WO2017210604A1 (en) 2017-12-07
CN109562186B (zh) 2022-09-13
CA3083596A1 (en) 2019-06-06
DK3454907T3 (da) 2020-10-19
EP3454907A1 (en) 2019-03-20
JP7130818B2 (ja) 2022-09-05
US10420843B2 (en) 2019-09-24
US20180200375A1 (en) 2018-07-19
JP7368354B2 (ja) 2023-10-24
EP3717451A1 (en) 2020-10-07
WO2019108605A1 (en) 2019-06-06
JP2019517582A (ja) 2019-06-24
US20180110751A1 (en) 2018-04-26
US20210138072A1 (en) 2021-05-13
AU2018374863A1 (en) 2020-06-11
JP2021504398A (ja) 2021-02-15
ES2827796T3 (es) 2021-05-24
US10130719B2 (en) 2018-11-20
EP3454907B1 (en) 2020-07-22
US11191840B2 (en) 2021-12-07
KR20190039034A (ko) 2019-04-10
US11135298B2 (en) 2021-10-05
CN109562186A (zh) 2019-04-02
KR102437682B1 (ko) 2022-08-29
US20200179521A1 (en) 2020-06-11
US20220031851A1 (en) 2022-02-03
CN111902394B (zh) 2024-03-08
AU2018374863B2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP6906047B2 (ja) 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP5043433B2 (ja) プロスタサイクリン類似体の送達のための化合物及び方法
JP2023030072A (ja) 併用療法
TWI508725B (zh) 脂肪酸富馬酸酯衍生物及其用途
JP2021505591A (ja) 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体
TW201902507A (zh) 治療病毒感染之組合療法
US9505709B2 (en) Compositions and methods relating to ionic salts of peptides
US12564644B2 (en) Cyclodextrin complexes of specialized proresolving mediators
US20200039980A1 (en) Rutaecarpine analogs and applications thereof
TW201620515A (zh) 作爲組織蛋白去乙醯酶抑制劑的單一鏡相異構物及其製備方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210628

R150 Certificate of patent or registration of utility model

Ref document number: 6906047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250